Dissecting the genetic basis of focal cortical dysplasia: a large cohort study.
Baldassari S, Ribierre T, Marsan E, Adle-Biassette H, Ferrand-Sorbets S, Bulteau C, Dorison N, Fohlen M, Polivka M, Weckhuysen S, Dorfmüller G, Chipaux M, Baulac S. · 2019
Read Dissecting the genetic basis of focal cortical dysplasia: a large cohort study. by Baldassari S, Ribierre T, Marsan E, Adle-Biassette H, Ferrand-Sorbets S, Bulteau C, Dorison N, Fohlen M, Polivka M, Weckhuysen S, Dorfmüller G, Chipaux M, Baulac S. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6851393.txt.
Introduction
Baldassari and co-authors report a large genetic study of focal cortical dysplasia, in Acta Neuropathologica. In this condition, part of the brain's cortex forms wrongly before birth. It is a major cause of severe childhood epilepsy that drugs cannot control, so surgery is often the only option. The malformed tissue holds swollen, abnormal neurons.
The team enrolled 80 children whose removed tissue confirmed one of these malformations. They sequenced target genes at very high depth in matched blood and brain samples. Both inherited variants and changes found only in the brain played a part. Sorting which genes drive which form of the condition should guide diagnosis and future treatment.
Catalog record
| CREATOR | Baldassari S, Ribierre T, Marsan E, Adle-Biassette H, Ferrand-Sorbets S, Bulteau C, Dorison N, Fohlen M, Polivka M, Weckhuysen S, Dorfmüller G, Chipaux M, Baulac S. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Dissecting the genetic basis of focal cortical dysplasia: a large cohort study By Sara Baldassari, Théo Ribierre, Elise Marsan, Homa Adle-Biassette, Sarah Ferrand-Sorbets, Christine Bulteau, Nathalie Dorison, Martine Fohlen, Marc Polivka, Sarah Weckhuysen, Georg Dorfmüller, Mathilde Chipaux Published in: Acta Neuropathologica DOI: 10.1007/s00401-019-02061-5 ABSTRACT Genetic malformations of cortical development (MCDs), such as mild MCDs (mMCD), focal cortical dysplasia (FCD), and hemimegalencephaly (HME), are major causes of severe pediatric refractory epilepsies subjected to neurosurgery. FCD2 are characterized by neuropathological hallmarks that include enlarged dysmorphic neurons (DNs) and balloon cells (BCs). Here, we provide a comprehensive assessment of the contribution of germline and somatic variants in a large cohort of surgical MCD cases. We enrolled in a monocentric study 80 children with drug-resistant epilepsy and a postsurgical neuropathological diagnosis of mMCD, FCD1, FCD2, or HME. We performed targeted gene sequencing ( ≥ 2000X read depth) on matched blood–brain samples to search for low-allele frequency variants in mTOR pathway and FCD genes. We were able to elucidate 29% of mMCD/FCD1 patients and 63% of FCD2/HME patients. Somatic loss-of-function variants in the N-glycosylation pathway-associated SLC35A2 gene were found in mMCD/FCD1 cases. Somatic gain-of-function variants in MTOR and its activators (AKT3, PIK3CA, RHEB), as well as germline, somatic and two-hit loss-of-function variants in its repressors (DEPDC5, TSC1, TSC2) were found exclusively in FCD2/HME cases. We show that panel-negative FCD2 cases display strong pS6-immunostaining, stressing that all FCD2 are mTORopathies. Analysis of microdissected cells demonstrated that DNs and BCs carry the pathogenic variants. We further observed a correlation between the density of pathological cells and the variant-detection likelihood. Single-cell microdissection followed by sequencing of enriched pools of DNs unveiled a somatic second-hit loss-of-heterozygosity in a DEPDC5 germline case. In conclusion, this study indicates that mMCD/FCD1 and FCD2/HME are two distinct genetic entities: while all FCD2/HME are mosaic mTORopathies, mMCD/FCD1 are not caused by mTOR-pathway-hyperactivating variants, and ~ 30% of the cases are related to glycosylation defects. We provide a framework for efficient genetic testing in FCD/HME, linking neuropathology to genetic findings and emphasizing the usefulness of molecular evaluation in the pediatric epileptic neurosurgical population. Electronic supplementary material The online version of this article (10.1007/s00401-019-02061-5) contains supplementary material, which is available to authorized users. INTRODUCTION Focal cortical dysplasia (FCD) and hemimegalencephaly (HME) are malformations of cortical development (MCDs) representing the most common cause of neocortical childhood-onset seizures [4, 14]. Seizures associated with FCD/HME are often refractory to antiepileptic drugs, and require surgical resection of the epileptogenic zone, allowing direct access to the dysplastic brain tissue for research purposes [8]. FCDs account for 17% of the children epilepsy surgery population, representing a major medical burden [6]. The international league against epilepsy (ILAE) has proposed a consensus for classification of FCDs based on neuropathological findings [7, 33]. FCD1 refers to isolated lesions with dyslamination of the neocortex. FCD2 refers to isolated lesions characterized by cortical dyslamination and dysmorphic neurons (DNs) in type 2a or both DNs and balloon cells (BCs) in type 2b. The most severe end of the spectrum is HME characterized by the enlargement of all or part of one cerebral hemisphere, often exhibiting FCD2a/2b histological features. In addition, mild forms of MCD (mMCDs) are characterized by an excess of heterotopic neurons in cortical layer 1 (mMCD type 1) or by microscopic neuronal clusters or excess of heterotopic single neurons of normal morphology in deep white matter (mMCD type 2) [7, 38]. Because of the focal nature of FCD, a role for somatic mosaic variants has been proposed [40]. Indeed, brain somatic variants in genes of the mTOR (mechanistic target of rapamycin) pathway have been reported in patients with various MCDs, from small FCD to larger HME [9, 10, 19, 25–27, 31, 32, 34, 39]. Hyperactivation of the mTOR pathway has been shown in FCD2/HME brain specimens (see reviews [18, 24, 29]), as well as in cellular and animal models of focal cortical expression of mutant MTOR or focal deletion of DEPDC5 [2, 16, 17, 27, 28, 34, 41]. The mTOR-signaling cascade plays a key role in the integration of various environmental signals to regulate cell growth, proliferation, and metabolism [23]. mTOR hyperactivation during neurodevelopment is assumed to cause the cellular hypertrophy observed in DNs and BCs. BCs are heterogeneous cell types and have been reported to express both neuronal and glial markers, while DNs express mostly Smi-32/Smi-311 neurofilament proteins [37, 43, 46]. However, it has never been proven that these pathological cells, underlying epileptogenesis, carry the disease-causing variants. Here, we report clinical, neuropathological, and molecular findings in a large monocentric cohort of 80 epileptic children subjected to neurosurgery and diagnosed with a cortical dysplasia (FCD or HME) or a mMCD. We designed a pipeline to efficiently detect low-allele frequency brain variants by capture-based gene panel sequencing, and accurately assess the prevalence of brain somatic and germline variants. Single-cell microdissection was performed to determine the cell type of origin of the variants. Finally, we performed a correlation analysis between clinicopathological features and genetic findings. METHODS Cohort recruitment and samples collection We enrolled 80 children subjected to surgery for the treatment of drug-resistant epilepsy at the Rothschild Foundation Hospital (Paris, France) between 2015 and 2018. The inclusion criterion was a post-operative diagnosis of mMCD, FCD or HME assessed by two experienced neuropathologists (H.A.B., M.P.). We collected clinical information before and after surgery for each patient. Presurgical MRI were systematically reviewed by a specialized neuroradiologist and by a pediatric epileptologist neurosurgeon (G.D. or S.F.S.). Subjects without precisely delimited MRI-lesions (58/80) underwent SEEG and/or 18-fluorodeoxyglucose positron emission tomography scan (18FDG-PET) investigation co-registered with MRI to further delineate the seizures onset zone (SOZ). A cognitive evaluation was conducted by the neuropediatricians (C.B., N.D., M.F., M.C.). Autistic features were defined by impairments in social interaction and communication, restricted interests and repetitive behaviors. Presurgical evaluation and surgical procedures were performed as previously reported [12]. After surgery, brain specimens were formalin-fixed and paraffin-embedded (FFPE) by the neuropathology department, and an adjacent block was immediately frozen in liquid nitrogen for research purposes. Neuropathological diagnoses were performed according to the ILAE guidelines [7]. FCD1 referred to isolated lesions with cortical dyslamination, and were classified as FCD1a when an excess of microcolumns was observed; FCD2a referred to cortical dyslamination and presence of DNs, and FCD2b referred to cortical dyslamination and presence of DNs and BCs. mMCD referred to surgical cases with blurred grey–white matter boundaries and excess of heterotopic neurons in cortical layer 1 (mMCD1) or in the deep white matter (mMCD2). Blood samples from patients and their parents (when available) were collected. Genomic DNA was extracted according to the standard procedures from blood samples and frozen brain sections or bulk tissue. This study was approved by the ethical committee CPP Ile de France II (N° ID-RCB/EUDRACT-2015-A00671-48) and is registered on ClinicalTrials.gov (N° NCT02890641). Written informed consent was obtained from all participants (or their parents on behalf). Detection and validation of somatic variants Hybrid capture sequencing targeting coding exons and exon-flanking junctions (10 bp) were performed (Roche NimbleGen SeqCapEZ Human custom panel). We used three updated versions of a panel comprising mTOR pathway and FCD candidate genes, including SLC35A2. Genes common to all versions are: AKT3 (NM_005465), DEPDC5 (NM_001242896), MIOS (NM_019005), MTOR (NM_004958), NPRL2 (NM_006545), NPRL3 (NM_001077350),